Full-Time

Director – Digital Media Analytics

GIACO Commercial Operations

Updated on 3/15/2025

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$188.6k - $282.9kAnnually

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid-Eligible: work remotely up to two days per week.

Category
General Marketing
Growth Marketing
Growth & Marketing
Required Skills
Python
R
SQL
Requirements
  • Bachelor’s degree required
  • 7+ years relevant experience in the US Pharmaceutical industry required
  • Minimum of 8 years of qualified work experience, including 5+ years in digital marketing analytics and media strategy
  • Deep expertise in cross-channel digital measurement operations with a laser-focused attention to detail in data capture and management
  • Solid background in digital measurement, exploratory analytics and insights generation across the digital media ecosystem (search, social, display, web, online video)
  • Solid understanding of advanced statistical measurement and analytics techniques, including strong familiarity with data mining and exploratory analytics tools such as SQL, R or Python
  • Highly collaborative in both operational and strategic environments
  • Strong attention to detail with high analytical horsepower
  • Strong communication skills (written and verbal) with the ability to translate findings into consumable and actionable insights and recommendations
Responsibilities
  • Lead the development and refinement of channel attribution models leveraging third-party budget planning tools to provide insights that guide optimal marketing spends that drive script lift and feed into Marketing Mix ROI attribution
  • Partner with our Director Omnichannel Analytics in the support of the upcoming product launch for the Pain Business Unit
  • Deliver impactful analyses and strategic recommendations to cross-functional teams to optimize the effectiveness and efficiency of multi-channel digital marketing tactics and campaigns, including endemic and non-endemic display/banner, social media, search, online video and TV
  • Lead the design, implementation and analysis of agile and actionable pilots and A/B tests that span across digital channels and leverage innovative targeting and segmentation strategies
  • Collaborate with media agency partners to shape and refine digital media strategies, ensuring campaigns are highly targeted, customer-focused and optimized for engagement
  • Partner closely with Data, Technology & Engineering teams to ensure media performance data is accurately transferred from third-party publishers into Vertex-hosted data platform and processed for accuracy and consistency
  • Explore opportunities to lead analyses that identify and establish data-driven best practices that can be leveraged as guiding principles for strategic customer engagement
  • Convert analytics into meaningful insights and strategic recommendations, delivering clear communication to both leadership and executional teams to drive informed decision-making
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna enhances its gene therapy capabilities.
  • Increased investments indicate strong investor confidence in Vertex's growth potential.
  • Vertex's global expansion includes a patient assistance program for Trikafta in South Africa.

What critics are saying

  • Vertex is under investigation for potential securities law violations.
  • Mixed Phase II results for suzetrigine may delay its development.
  • The $1.07 billion Orna partnership could strain resources if unsuccessful.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative gene-editing therapies target sickle cell disease and beta thalassemia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

MarketBeat
Jan 17th, 2025
Channel Wealth LLC Invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Channel Wealth LLC invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Zenopa
Jan 8th, 2025
Vertex and Orna Partner for Innovative Gene Therapy Solutions

In a significant advancement for the biopharma industry, Vertex Pharmaceuticals has announced a partnership with Orna Therapeutics to develop cutting-edge in vivo gene editing therapies targeting sickle cell disease and beta thalassaemia.

Pipeline Review
Jan 8th, 2025
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

We look forward to partnering with Vertex to develop transformative therapies for SCD and TDT, while simultaneously advancing our lead panCAR(TM) pipeline programs in autoimmune and oncology.

Precision Medicine Online
Jan 7th, 2025
Vertex Gains Rights to Orna Therapeutics' Drug Delivery Tech in $1.07B Deal

NEW YORK - Orna Therapeutics on Tuesday said it has inked a deal with Vertex Pharmaceuticals valued at more than $1.07 billion, in which Vertex will use its drug delivery technology to develop new gene-editing treatments for patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).